Cancer stem cells and tumor heterogeneity: Deciphering the role in tumor progression and metastasis
- PMID: 35872504
- DOI: 10.1016/j.cyto.2022.155968
Cancer stem cells and tumor heterogeneity: Deciphering the role in tumor progression and metastasis
Abstract
Tumor heterogeneity, in principle, reflects the variation among different cancer cell populations. It can be termed inter- or intra-tumoral heterogeneity, respectively, based on its occurrence in various tissues from diverse patients or within a single tumor. The intra-tumoral heterogeneity is one of the leading causes of cancer progression and treatment failure, with the cancer stem cells (CSCs) contributing immensely to the same. These niche cells, similar to normal stem cells, possess the characteristics of self-renewal and differentiation into multiple cell types. Moreover, CSCs contribute to tumor growth and surveillance by promoting recurrence, metastasis, and therapeutic resistance. Diverse factors, including intracellular signalling pathways and tumor microenvironment (TME), play a vital role in regulating these CSCs. Although a panel of markers is considered to identify the CSC pool in various cancers, further research is needed to discriminate cancer-specific CSC markers in those. CSCs have also been found to be promising therapeutic targets for cancer therapy. Several small molecules, natural compounds, antibodies, chimeric antigen receptor T (CAR-T) cells, and CAR-natural killer (CAR-NK) cells have emerged as therapeutic tools for specific targeting of CSCs. Interestingly, many of these are in clinical trials too. Despite being a much-explored avenue of research for years, and we have come to understand its nitty-gritty, there is still a tremendous gap in our knowledge concerning its precise genesis and regulation. Hence, a concrete understanding is needed to assess the CSC-TME link and how to target different cancer-specific CSCs by designing newer tools. In this review, we have summarized CSC, its causative, different pathways and factors regulating its growth, association with tumor heterogeneity, and last but not least, discussed many of the promising CSC-targeted therapies for combating cancer metastasis.
Keywords: Cancer stem cells; Tumor heterogeneity; Tumor microenvironment.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Similar articles
-
Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review.Cells. 2020 Aug 13;9(8):1896. doi: 10.3390/cells9081896. Cells. 2020. PMID: 32823711 Free PMC article. Review.
-
Characteristics of the cancer stem cell niche and therapeutic strategies.Stem Cell Res Ther. 2022 Jun 3;13(1):233. doi: 10.1186/s13287-022-02904-1. Stem Cell Res Ther. 2022. PMID: 35659296 Free PMC article. Review.
-
Cancer stem cells (CSCs) in cancer progression and therapy.J Cell Physiol. 2019 Jun;234(6):8381-8395. doi: 10.1002/jcp.27740. Epub 2018 Nov 11. J Cell Physiol. 2019. PMID: 30417375 Review.
-
Stem cell programs in cancer initiation, progression, and therapy resistance.Theranostics. 2020 Jul 9;10(19):8721-8743. doi: 10.7150/thno.41648. eCollection 2020. Theranostics. 2020. PMID: 32754274 Free PMC article. Review.
-
Cancer stem cells and tumor-associated macrophages as mates in tumor progression: mechanisms of crosstalk and advanced bioinformatic tools to dissect their phenotypes and interaction.Front Immunol. 2025 Feb 6;16:1529847. doi: 10.3389/fimmu.2025.1529847. eCollection 2025. Front Immunol. 2025. PMID: 39981232 Free PMC article. Review.
Cited by
-
Prediction of synergistic gemcitabine-based combination treatment through a novel tumor stemness biomarker NANOG in pancreatic cancer.RSC Med Chem. 2024 Sep 5;15(11):3853-61. doi: 10.1039/d4md00165f. Online ahead of print. RSC Med Chem. 2024. PMID: 39297058 Free PMC article.
-
Liver organoids and their application in liver cancer research.Regen Ther. 2023 Dec 23;25:128-137. doi: 10.1016/j.reth.2023.12.011. eCollection 2024 Mar. Regen Ther. 2023. PMID: 38226058 Free PMC article. Review.
-
Mesenchymal stem/stromal cells- a principal element for tumour microenvironment heterogeneity.Front Immunol. 2023 Oct 9;14:1274379. doi: 10.3389/fimmu.2023.1274379. eCollection 2023. Front Immunol. 2023. PMID: 37885883 Free PMC article. Review.
-
Cancer stem cell fate determination: mito-nuclear communication.Cell Commun Signal. 2023 Jun 27;21(1):159. doi: 10.1186/s12964-023-01160-x. Cell Commun Signal. 2023. PMID: 37370081 Free PMC article. Review.
-
Nuclear receptor NURR1 functions to promote stemness and epithelial-mesenchymal transition in prostate cancer via its targeting of Wnt/β-catenin signaling pathway.Cell Death Dis. 2024 Mar 26;15(3):234. doi: 10.1038/s41419-024-06621-w. Cell Death Dis. 2024. PMID: 38531859 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous